Ligand-targeted liposomes

Advanced Drug Delivery Reviews

Volumn 29, Issue 3, 1998, Pages 249-271

  Forssen, Eric ^a   Willis, Michael ^b  

^a NeXstar Pharmaceuticals Inc   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

Immunoglobulins; In vivo drug delivery; Liposomes; Oligonucleotide aptamers; Peptide targeting

Indexed keywords

MACROMOLECULES; OLIGOMERS; POLYPEPTIDES; PROTEINS;

IMMUNOGLOBULINS; LIGANDS; LIPOSOMES; OLIGONUCLEOTIDE APTAMERS;

CONTROLLED DRUG DELIVERY;

AMIKACIN; AMPHOTERICIN B LIPID COMPLEX; ANNAMYCIN; ANTIBODY; CELL ADHESION MOLECULE; DAUNORUBICIN; DOXORUBICIN; INTEGRIN; LIPOSOME; MURAMYL TRIPEPTIDE; NYSTATIN; PROSTAGLANDIN E1; RECEPTOR; RETINOIC ACID; SELECTIN;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; ENDOCYTOSIS; LIGAND BINDING; PRIORITY JOURNAL; REVIEW; TARGET ORGAN; TECHNOLOGY;

EID: 0032472802     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00083-5     Document Type: Review

References (135)

1. E. Tomlinson, (Patho)physiology and the temporal and spatial aspects of drug delivery, in: E. Tomlinson and S.S. Davis (Eds.), Site-specific Drug Delivery: Cell Biology, Medical and Pharmaceutical Aspects, J. Wiley and Sons, Chichester, 1986, pp. 1-26.
2. C.H. Blesing, D.J. Kerr, Intra-hepatic arterial drug delivery, J Drug Targeting 3 (1996) 341-347.
3. A.M. Averbach, P.H. Sugarbaker, Methodologie considerations in treatment using intraperitoneal chemotherapy, Cancer Treat Res (Netherlands) 82 (1996) 289-309.
4. D. Fennelly, J. Schneider, Role of chemotherapy dose intensification in the treatment of advanced ovarian cancer. Oncology (Huntingt) 9 (1995) 911-21; discussion 922, 924, 926.
5. H.R. Alexander Jr., D.L. Fraker, D.L. Bartlett, Isolated limb perfusion for malignant melanoma, Semin Surg Oncol 12 (1996) 416-428.
6. A. Gabizon, D.C. Price, J. Huberty, R.S. Bresalier, D. Papahadjopoulos, Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies, Cancer Res 50 (1990) 6371-6378.
7. Y. Banno, K. Ohki, T. Morita, S. Yoshioka, Y. Nozawa, Involvement of the membrane fluidity of lactosylceramide-targeted liposomes in their intrahepatic uptake, Biochem Int 12 (1986) 865-871.
8. K.D. Lee, K. Hong, D. Papahadjopoulos, Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density, Biochim Biophys Acta 1103 (1992) 185-197.
9. G. Gregoriadis, C. Davis, Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells, Biochem Biophys Res Commun 89 (1979) 1287-1293.
10. N. Emanuel, E. Kedar, E.M. Bolotin, N.I. Smorodinsky, Y. Barenholz, Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes, Pharm Res 13 (1996) 352-359.
11. 1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo, FEBS Lett 284 (1991) 263-266.
12. D.J. Buchsbaum, Experimental approaches to increase radio-labeled antibody localization in tumors, Cancer Res 55 (1995) 5729s-5732s.
13. T.M. Behr, R.M. Sharkey, M.I. Juweid, R.M. Dunn, Z. Ying, C.H. Zhang, J.A. Siegel, D.V. Gold et al., Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors, Cancer Res 56 (1996) 1805-1816.
14. I. Ogihara-Umeda, T. Sasaki, H. Toyama, K. Oda, M. Senda, H. Nishigori, Rapid tumor imaging by active background reduction using biotin-bearing liposomes and avidin, Cancer Res 54 (1994) 463-467.
15. I. Ogihara-Umeda, T. Sasaki, H. Nishigori, Active removal of radioactivity in the blood circulation using biotin-bearing liposomes and avidin for rapid tumour imaging, Eur J Nucl Med 20 (1993) 170-172.
16. K. Fujimori, D.G. Covell, J.E. Fletcher, J.N. Weinstein, Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors, Cancer Res (United States) 49 (1989) 5656-5663.
17. E.A. Forssen, D.M. Coulter, R.T. Proffitt, Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors, Cancer Res 52 (1992) 3255-3261.
18. A.A. Gabizon, Y. Barenholz, M. Bialer, Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs, Pharm Res 10 (1993) 703-708.
19. C.R. Alving, E.A. Steck, W.L. Chapman Jr., V.B. Waits, L.D. Hendricks, G.M. Swartz Jr., W.L. Hanson, Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs, Proc Natl Acad Sci USA 75 (1978) 2959-2963.
20. C.R. Alving, E.A. Steck, W.L. Hanson, P.S. Loizeaux, W.L. Chapman Jr., V.B. Waits, Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug, Life Sci 22 (1978) 1021-1026.
21. C.R. Alving, E.A. Steck, W.L. Chapman Jr., V.B. Waits, L.D. Hendricks, G.M. Swartz Jr., W.L. Hanson, Liposomes in leishmaniasis: therapeutic effects of antimonial drugs, 8-aminoquinolines, and tetracycline, Life Sci 26 (1980) 2231-2238.
22. J.S. Weldon, J.F. Munnell, W.L. Hanson, C.R. Alving, Liposomal chemotherapy in visceral leishmaniasis: an ultra-structural study of an intracellular pathway, Z Parasitenkd 69 (1983) 415-424.
23. M.J. Gilbreath, C.A. Nacy, D.L. Hoover, C.R. Alving, G.M. Swartz Jr., M.S. Meltzer, Macrophage activation for microbicidal activity against Leishmania major: inhibition of lymphokine activation by phosphatidylcholine-phosphatidylserine liposomes, J Immunol 134 (1985) 3420-3425.
24. C.R. Alving, G.M. Swartz Jr., L.D. Hendricks, W.L. Chapman Jr., V.B. Waits, W.L. Hanson, Liposomes in leishmaniasis: effects of parasite virulence on treatment of experimental leishmaniasis in hamsters, Ann Trop Med Parasitol 78 (1984) 279-286.
25. W.L. Chapman Jr., W.L. Hanson, C.R. Alving, L.D. Hendricks, Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog, Am J Vet Res 45 (1984) 1028-1030.
26. J.D. Berman, W.L. Hanson, W.L. Chapman, C.R. Alving, G. Lopez-Berestein, Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys, Antimicrob Agents Chemother 30 (1986) 847-851.
27. M.J. Gilbreath, D.L. Hoover, C.R. Alving, G.M. Swartz Jr., M.S. Meltzer, Inhibition of lymphokine-induced macrophage microbicidal activity against Leishmania major by liposomes: characterization of the physicochemical requirements for liposome inhibition, J Immunol 137 (1986) 1681-1687.
28. M.J. Gilbreath, W.E. Fogler, G.M. Swartz Jr., C.R. Alving, M.S. Meltzer, Inhibition of interferon gamma-induced macrophage microbicidal activity against Leishmania major by liposomes: inhibition is dependent upon composition of phospholipid headgroups and fatty acids, Int J Immunopharmacol 11 (1989) 103-110.
29. I.J. Fidler, The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process, J Immunol 127 (1981) 1719-1720.
30. I.J. Fidler, S. Sone, W.E. Fogler, Z.L. Barnes, Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide, Proc Natl Acad Sci USA 78 (1981) 1680-1684.
31. S. Sone, I.J. Fidler, In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes, Cell Immunol 57 (1981) 42-50.
32. S. Sone, I.J. Fidler, Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages, J Immunol 125 (1980) 2454-2460.
33. I.J. Fidler, Z. Barnes, W.E. Fogler, R. Kirsh, P. Bugelski, G. Poste, Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators, Cancer Res 42 (1982) 496-501.
34. I.J. Fidler, W.E. Fogler, A.F. Brownbill, G. Schumann, Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide, J Immunol 138 (1987) 4509-4514.
35. W.E. Fogler, I.J. Fidler, The activation of tumoricidal properties in human blood monocytes by muramyl dipeptide requires specific intracellular interaction, J Immunol 136 (1986) 2311-2317.
36. R. Nayar, K. Morikawa, I.J. Fidler, Characterization of liposomes containing the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) and their interaction with mouse macrophages, Cancer Drug Deliv 4 (1987) 233-244.
37. W. van Osdol, K. Fujimori, J.N. Weinstein, An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier", Cancer Res 51 (1991) 4776-4784.
38. K. Fujimori, D.G. Covell, J.E. Fletcher, J.N. Weinstein, A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier, J Nucl Med (United States) 31 (1990) 1191-1198.
39. K.A. Kennedy, B.A. Teicher, S. Rockwell, A.C. Sartorelli, The hypoxic tumor cell: a target for selective cancer chemotherapy, Biochem Pharmacol (England) 29 (1980) 1-8.
40. W.G. Roberts, G.E. Palade, Neovasculature induced by vascular endothelial growth factor is fenestrated, Cancer Res 57 (1997) 765-772.
41. D. Hanahan, J. Folkman, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell 86 (1996) 353-364.
42. J. Folkman, P.A. D'Amore, Blood vessel formation: What is its's molecular basis?, Cell 87 (1996) 1153-1155.
43. R.T. Proffitt, L.E. Williams, C.A. Presant, G.W. Tin, J.A. Uliana, R.C. Gamble, J.D. Baldeschwieler, Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles, Science 220 (1983) 502-505.
44. R.T. Proffitt, L.E. Williams, C.A. Presant, G.W. Tin, J.A. Uliana, R.C. Gamble, J.D. Baldeschwieler, Tumor-imaging potential of liposomes loaded with In-111-NTA: biodistribution in mice, J Nucl Med 24 (1983) 45-51.
45. L.E. Williams, R.T. Proffitt, L. Lovisatti, Possible applications of phospholipid vesicles (liposomes) in diagnostic radiology, J Nucl Med Allied Sci 28 (1984) 35-45.
46. R.K. Jain, Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors, Cancer Res 50 (1990) 814s-819s.
47. R.C. Jackson, in: Computer Techniques in Preclinical and Clinical Drug Development, CRC Press, Boca Raton, 1996, pp. 238.
48. C.A. Hunt, Y.M. Rustum, E. Mayhew, D. Papahadjopoulos, Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size, Drug Metab Dispos 7 (1979) 124-128.
49. T.M. Allen, I. Ahmad, D.E. Lopes de Menezes, E.H. Moase, Immunoliposome-mediated targeting of anti-cancer drugs in vivo, Biochem Soc Trans (England) 23 (1995) 1073-1079.
50. I. Ahmad, M. Longenecker, J. Samuel, T.M. Allen, Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice, Cancer Res 53 (1993) 1484-1488.
51. J.N. Weinstein, R.R. Eger, D.G. Covell, C.D. Black, J. Mulshine, J.A. Carrasquillo, S.M. Larson, A.M. Keenan, The pharmacology of monoclonal antibodies, Ann New York Acad Sci (United States) 507 (1987) 199-210.
52. C. Kirby, J. Clarke, G. Gregoriadis, Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum, FEBS Lett 111 (1980) 324-328.
53. N.J. Zuidam, H.K. Gouw, Y. Barenholz, D.J. Crommelin, Physical (in)stability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids, Biochim Biophys Acta 1240 (1995) 101-110.
54. + ions, Biol Chem Hoppe Seyler 370 (1989) 1315-1320.
55. R. Almog, R. Forward, C. Samsonoff, Stability of sonicated aqueous suspensions of phospholipids under air, Chem Phys Lipids 60 (1991) 93-99.
56. J. Mattai, P.K. Sripada, G.G. Shipley, Mixed-chain phosphatidylcholine bilayers: structure and properties, Biochemistry 26 (1987) 3287-3297.
57. H.M. Patel, Serum opsonins and liposomes: their interaction and opsonophagocytosis, Crit Rev Ther Drug Carrier Syst 9 (1992) 39-90.
58. A. Gabizon, D. Papahadjopoulos, Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors, Proc Natl Acad Sci USA 85 (1988) 6949-6953.
59. G.K. Miller, G.S. Naeve, S.A. Gaffar, A.L. Epstein, Immunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones, Hybridoma 12 (1993) 689-698.
60. A.L. Epstein, L.A. Khawli, J.L. Hornick, C.R. Taylor, Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin 2, Cancer Res 55 (1995) 2673-2680.
61. P.G. Bloemen, P.A. Henricks, L. van Bloois, M.C. van den Tweel, A.C. Bloem, F.P. Nijkamp, D.J. Crommelin, G. Storm, Adhesion molecules: a new target for immuno-liposome-mediated drug delivery, FEBS Lett 357 (1995) 140-144.
62. M. Friedlander, C.L. Theesfeld, M. Sugita, M. Fruttiger, M.A. Thomas, S. Chang, D.A. Cheresh, Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases, Proc Natl Acad Sci USA 93 (1996) 9764-9769.
63. F.M. Chen, J.R.J. Wisner, H. Omachi, I.G. Renner, C.R. Taylor, A.L. Epstein, Localization of monoclonal antibody TNT-1 in experimental kidney infarction of the mouse, FASEB J (United States) 4 (1990) 3033-3039.
64. 131I-labeled TNT-1 radioimmunotherapy on HT-29 human colon adenocarcinoma spheroids, Cancer Immunol Immunother (Germany) 33 (1991) 158-164.
65. F.M. Cheng, E.B. Hansen, C.R. Taylor, A.L. Epstein, Diffusion and binding of monoclonal antibody TNT-1 in multicellular tumor spheroids, J Natl Cancer Inst (United States) 83 (1991) 200-204.
66. B.A. Khaw, V.P. Torchilin, I. Vural, J. Narula, Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes, Nat Med 1 (1995) 1195-1198.
67. R.J. Lee, P.S. Low, Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis, J Biol Chem 269 (1994) 3198-3204.
68. R.J. Lee, P.S. Low, Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro, Biochim Biophys Acta 1233 (1995) 134-144.
69. R.J. Lee, L. Huang, Folate-targeted, anionic liposome-en-trapped polylysine-condensed DNA for tumor cell-specific gene transfer, J Biol Chem 271 (1996) 8481-8487.
70. Q.H. Sun, H.M. De Lisser, M.M. Zukowski, C. Paddock, S.M. Albelda, P.J. Newman, Individually distinct Ig homology domains in PECAM-1 regulate homophilic binding and modulate receptor affinity, J Biol Chem 271 (1996) 11090-11098.
71. RS. Frenette, D.D. Wagner, Adhesion molecules - Part 1, New Engl J Med 334 (1996) 1526-1529.
72. J. Willems, E. Bruyneel, V. Noe, H. Slegers, A. Zwijsen, R.M. Mege, M. Mareel, Cadherin-dependent cell aggregation is affected by decapeptide derived from rat extracellular super-oxide dismutase, FEBS Lett 363 (1995) 289-292.
73. M. Mareel, G. Berx, F. Van Roy, M. Bracke, Cadherin/ catenin complex: a target for antiinvasive therapy?, J Cell Biochem 61 (1996) 524-530.
74. E. Ruoslahti, Integrin signaling and matrix assembly, Tumour Biol 17 (1996) 117-124.
75. R.C. Bates, L.F. Lincz, G.F. Burns, Involvement of integrins in cell survival, Cancer Metastasis Rev 14 (1995) 191-203.
76. J.A. Varner, P.C. Brooks, D.A. Cheresh, Review: the integrin alpha V beta 3: angiogenesis and apoptosis, Cell Adhes Commun 3 (1995) 367-374.
77. E.H. Danen, A.A. van Kraats, I.M. Cornelissen, D.J. Ruiter, G.N. van Muijen, Integrin beta 3 cDNA transfection into a highly metastatic alpha v beta 3-negative human melanoma cell line inhibits invasion and experimental metastasis, Biochem Biophys Res Commun 226 (1996) 75-81.
78. E.J. Filardo, P.C. Brooks, S.L. Deming, C. Damsky, D.A. Cheresh, Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo, J Cell Biol 130 (1995) 441-450.
79. C.J. Drake, D.A. Cheresh, C.D. Little, An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization, J Cell Sci 108 (1995) 2655-2661.
80. D.A. Sipkins, P.C. Brooks, D.A. Cheresh, K.P.C. Li, and M.D. Bednarski, Development of a new angiogenesis-specific liposome particle for use in diagnostic imaging and drug delivery. AACR Proceedings (1996), Washington, D.C. Am. Assoc. for Cancer Res.
81. I. Saiki, C. Koike, A. Obata, H. Fujii, J. Murata, M. Kiso, A. Hasegawa, H. Komazawa et al., Functional role of sialyl Lewis X and fibronectin-derived RGDS peptide analogue on tumor-cell arrest in lungs followed by extravasation, Int J Cancer 65 (1996) 833-839.
82. N. Oku, Y. Tokudome, C. Koike, N. Nishikawa, H. Mori, I. Saiki, S. Okada, Liposomal Arg-Gly-Asp analogs effectively inhibit metastatic B16 melanoma colonization in murine lungs, Life Sci 58 (1996) 2263-2270.
83. T. Nishiya, S. Sloan, Interaction of RGD liposomes with platelets, Biochem Biophys Res Commun 224 (1996) 242-245.
84. S. Zalipsky, B. Puntambekar, P. Boulikas, C.M. Engbers, M.C. Woodle, Peptide attachment to extremities of liposomal surface grafted PEG chains: preparation of the long-circulating form of laminin pentapeptide, YIGSR, Bioconjug Chem 6 (1995) 705-708.
85. P.S. Frenette, D.D. Wagner, Adhesion molecules - Part II: Blood vessels and blood cells, New Engl J Med 335 (1996) 43-45.
86. M.P. Bevilacqua, R.M. Nelson, Selectins, J Clin Invest 91 (1993) 379-387.
87. S.D. Rosen, C.R. Bertozzi, The selectins and their ligands, Curr Opin Cell Biol 6 (1994) 663-673.
88. T.A. Springer, Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm, Cell 76 (1994) 301-314.
89. L.A. Lasky, Selectin-carbohydrate interactions and the initiation of the inflammatory response, Annu Rev Biochem 64 (1995) 113-139.
90. T.M. Carlos, J.M. Harlan, Leukocyte-endothelial adhesion molecules, Blood 84 (1994) 2068-2101.
91. R.M. Nelson, A. Venot, M.P. Bevilacqua, R.J. Linhardt, I. Stamenkovic, Carbohydrate-protein interactions in vascular biology, Annu Rev Cell Dev Biol 11 (1995) 601-631.
92. S.M. Albelda, C.W. Smith, P.A. Ward, Adhesion molecules and inflammatory injury, FASEB J 8 (1994) 504-512.
93. M.P. Bevilacqua, R.M. Nelson, G. Mannori, O. Cecconi, Endothelial-leukocyte adhesion molecules in human disease, Annu Rev Med 45 (1994) 361-378.
94. A.M. Lefer, A.S. Weyrich, M. Buerke, Role of selectins, a new family of adhesion molecules, in ischaemia-reperfusion injury, Cardiovasc Res 28 (1994) 289-294.
95. C. Foxall, S.R. Watson, D. Dowbenko, C. Fennie, L.A. Lasky, M. Kiso, A. Hasegawa, D. Asa et al., The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide, J Cell Biol 117 (1992) 895-902.
96. E.L. Berg, M.K. Robinson, O. Mansson, E.C. Butcher, J.L. Magnani, A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1, J Biol Chem 266 (1991) 14869-14872.
97. N. Oku, C. Koike, Y. Tokudome, S. Okada, N. Nishikawa, H. Tsukada, M. Kiso, A. Hasegawa et al., Application of liposomes for cancer metastasis, Adv. Drug Deliv. Rev. 24 (1997) 215-223.
98. C.M. Cohen, G. Weissmann, S. Hoffstein, Y.C. Awasthi, S.K. Srivastava, Introduction of purified hexosaminidase A into Tay-Sachs leukocytes by means of immunoglobulin-coated liposomes, Biochemistry 15 (1976) 452-460.
99. G. Weissmann, D. Bloomgarden, R. Kaplan, C. Cohen, S. Hoffstein, T. Collins, A. Gotlieb, D. Nagle, A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells, Proc Natl Acad Sci USA 72 (1975) 88-92.
100. G. Weissmann, T. Collins, A. Evers, P. Dunham, Membrane perturbation: studies employing a calcium-sensitive dye, arsenazo III, in liposomes, Proc Natl Acad Sci USA 73 (1976) 510-514.
101. G. Weissmann, Experimental enzyme replacement in genetic and other disorders, Hosp Pract (United States) 11 (1976) 49-58.
102. L.D. Leserman, J.N. Weinstein, R. Blumenthal, S.O. Sharrow, W.D. Terry, Binding of antigen-bearing fluorescent liposomes to the murine myeloma tumor MOPC 315, J Immunol 122 (1979) 585-591.
103. L.D. Leserman, J.N. Weinstein, J.J. Moore, W.D. Terry, Specific interaction of myeloma tumor cells with hapten-bearing liposomes containing methotrexate and carboxyfluorescein, Cancer Res 40 (1980) 4768-4774.
104. L. Leserman, Side chains and magic bullets: Paul Ehrlich revisited, in: G. Gregoriadis (Ed.), Liposomes as Drug Carriers: Recent Trends and Progress, Wiley, Chichester, 1988, pp. 719-726.
105. L.D. Leserman, J.N. Weinstein, R. Blumenthal, W.D. Terry, Receptor-mediated endocytosis of antibody-opsonized liposomes by tumor cells, Proc Natl Acad Sci USA 77 (1980) 4089-4093.
106. P. Machy, L.D. Leserman, Small liposomes are better than large liposomes for specific drug delivery in vitro, Biochim Biophys Acta 730 (1983) 313-320.
107. A. Truneh, Z. Mishal, L.D. Leserman, A calmodulin antagonist increases the apparent rate of endocytosis of liposomes bound to MHC molecules via monoclonal antibodies, Exp Cell Res 155 (1984) 50-63.
108. K. Avrilionis, J.M. Boggs, Specific targeting of phototoxic haptenated liposomes to a hapten-specific B cell lymphoma, Cell Immunol 168 (1996) 13-23.
109. M.B. Rosenberg, X.O. Breakefield, E. Hawrot, Targeting of liposomes to cells bearing nerve growth factor receptors mediated by biotinylated nerve growth factor, J Neurochem 48 (1987) 865-875.
110. L.D. Leserman, J. Barbet, F. Kourilsky, J.N. Weinstein, Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A, Nature 288 (1980) 602-604.
111. F.J. Martin, T.D. Heath, R.R.C. New, Covalent attachment of proteins to liposomes, in: R.R.C. New (Ed.), Liposomes, a practical approach. IRL Press at Oxford University Press, Oxford, 1992, pp. 163-182.
112. S.M. Ansell, P.G. Tardi, S.S. Buchkowsky, 3-(2-Pyridyldithio)propionic acid hydrazide as a cross-linker in the formation of liposome-antibody conjugates, Bioconjug Chem 7 (1996) 490-496.
113. S. Arab, C.A. Lingwood, Influence of phospholipid chain length on verotoxin/globotriaosyl ceramide binding in model membranes: comparison of a supported bilayer film and liposomes, Glycoconj J 13 (1996) 159-166.
114. J.T. Derksen, H.W. Morselt, G.L. Scherphof, Uptake and processing of immunoglobulin-coated liposomes by sub-populations of rat liver macrophages, Biochim Biophys Acta 971 (1988) 127-136.
115. D. Aragnol, L.D. Leserman, Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo, Proc Natl Acad Sci USA 83 (1986) 2699-2703.
116. J.D. Baldeschwieler, Phospholipid vesicle targeting using synthetic glycolipid and other determinants, Ann New York Acad Sci 446 (1985) 349-367.
117. S.M. Moghimi, H.M. Patel, Differential properties of organ-specific serum opsonins for liver and spleen macrophages, Biochim Biophys Acta 984 (1989) 379-383.
118. A.C. Allison, N.E. Byars, Adjuvant formulations and their mode of action, Semin Immunol 2 (1990) 369-374.
119. C.R. Alving, Liposomes as carriers of antigens and adjuvants, J Immunol Methods 140 (1991) 1-13.
120. N. van Rooijen, R. van Nieuwmegen, Liposomes in immunology: evidence that their adjuvant effect results from surface exposition of the antigens, Cell Immunol 49 (1980) 402-407.
121. T.D. Heath, D.C. Edwards, B.E. Ryman, The adjuvant properties of liposomes, Biochem Soc Trans 4 (1976) 129-133.
122. K. Maruyama, S.J. Kennel, L. Huang, Lipid composition is important for highly efficient target binding and retention of immunoliposomes, Proc Natl Acad Sci USA 87 (1990) 5744-5748.
123. A.L. Klibanov, K. Maruyama, A.M. Beckerleg, V.P. Torchilin, L. Huang, Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target, Biochim Biophys Acta 1062 (1991) 142-148.
124. V.P. Torchilin, A.L. Klibanov, L. Huang, O.D. S, N.D. Nossiff, B.A. Khaw, Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium, FASEB J 6 (1992) 2716-2719.
125. V.P. Torchilin, Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents, Immunomethods 4 (1994) 244-258.
126. T.M. Allen, E. Brandeis, C.B. Hansen, G.Y. Kao, S. Zalipsky, A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells, Biochim Biophys Acta 1237 (1995) 99-108.
127. P.S. Uster, T.M. Allen, B.E. Daniel, C.J. Mendez, M.S. Newman, G.Z. Zhu, Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time, FEBS Lett (Netherlands) 386 (1996) 243-246.
128. C.B. Hansen, G.Y. Kao, E.H. Moase, S. Zalipsky, T.M. Allen, Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures, Biochim Biophys Acta 1239 (1995) 133-144.
129. L. Gold, Conformational properties of oligonucleotides, Nucleic Acids Symp Ser 33 (1995) 20-22.
130. L. Gold, Oligonucleotides as research, diagnostic, and therapeutic agents, J Biol Chem 270 (1995) 13581-13584.
131. L. Gold, J. Alper, Keeping pace with genomics through combinatorial chemistry, Nature Biotechnology 15 (1997) 297-298.
132. L. Gold, B. Polisky, O. Uhlenbeck, M. Yarus, Diversity of oligonucleotide functions, Annu Rev Biochem 64 (1995) 763-797.
133. T. Fitzwater, B. Polisky, A SELEX primer, Methods Enzymol 267 (1996) 275-301.
134. B.J. Hicke, S.R. Watson, A. Koenig, C.K. Lynott, R.F. Bargatze, Y.F. Chang, S. Ringquist, L. Moon-McDermott et al., DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice, J Clin Invest 98 (1996) 2688-2692.
135. N. Janjic, P.S. Gill, M.C. Willis, J. Cai, D.P. Sebesta, T. Zheng, B. Collins, L.S. Green et al., Liposomal aptamer antagonists of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), in: A.T. Florence (Ed.) Liposome Advances: Progress in Drug and Vaccine Delivery. Centre for Drug Delivery Research, School of Pharmacy, University of London, 1996, London.